Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign” - 23/07/20
Doi : 10.1016/j.jaad.2020.05.079
Carlos Gustavo Wambier, MD, PhD a, ⁎ 
, Sergio Vaño-Galván, MD, PhD b, John McCoy, PhD c, Alba Gomez-Zubiaur, MD d, Sabina Herrera, MD, PhD e, Ángela Hermosa-Gelbard, MD b, Oscar M. Moreno-Arrones, MD, PhD b, Natalia Jiménez-Gómez, MD b, Alvaro González-Cantero, MD, PhD b, Pablo Fonda-Pascual, MD f, Gonzalo Segurado-Miravalles, MD b, Jerry Shapiro, MD g, Bibiana Pérez-García, MD, PhD b, Andy Goren, MD c
, Sergio Vaño-Galván, MD, PhD b, John McCoy, PhD c, Alba Gomez-Zubiaur, MD d, Sabina Herrera, MD, PhD e, Ángela Hermosa-Gelbard, MD b, Oscar M. Moreno-Arrones, MD, PhD b, Natalia Jiménez-Gómez, MD b, Alvaro González-Cantero, MD, PhD b, Pablo Fonda-Pascual, MD f, Gonzalo Segurado-Miravalles, MD b, Jerry Shapiro, MD g, Bibiana Pérez-García, MD, PhD b, Andy Goren, MD c a Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island
b Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain
c Applied Biology, Inc, Irvine, California
d Dermatology Department, Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
e Infectious Diseases Unit, Ramón y Cajal Hospital, Madrid, Spain
f Dermatology Department, Hospital Central de la Defensa, Madrid, Spain
g Ronald O. Perelman Department of Dermatology at the New York University School of Medicine, New York, New York
∗Correspondence to: Carlos Gustavo Wambier, MD, PhD, Department of Dermatology, Rhode Island Hospital, 593 Eddy St, APC Bldg, 10th Floor, Providence, RI, 02903Department of DermatologyRhode Island Hospital593 Eddy St, APC Bldg, 10th FloorProvidenceRI02903
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Graphical abstract |
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 2
P. 680-682 - août 2020 Retour au numéro
Article précédent
- The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
- Marilyn T. Wan, Daniel B. Shin, Kevin L. Winthrop, Joel M. Gelfand
- Retrospective analysis of smell and taste disturbances associated with dermatologic medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections
- Yu Wang, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.